Abstract Library

#4417 Efficacy of immune checkpoint inhibitors (ICI) in patients with advanced pancreatic NETs displaying high TMB and MMR alterations following treatment with alkylating agents

Introduction: Alkylating chemotherapy (ALK) is frequently used in patients with PanNETs. It may favour grade progression and acquisition of a hypermutator phenotype associated with frequent alterations of the MMR genes, suggesting a potential benefit of ICI.

Conference:

Presenting Author:

Authors: de Mestier L, Apostolidis L, Koumarianou A, Hernando Cubero J, Riechelmann R,

Keywords: immune checkpoint inhibitor, immunotherapy, hypermutagenicity, alkylating agents, tumour mutational burden, mismatch repair,

#4392 Updated results of first-line chemotherapy combined with an immune checkpoint inhibitor for advanced extrapulmonary neuroendocrine carcinoma: A single arm, phase II study

Introduction: NEC is a rare, aggressive cancer with limited response to standard first-line chemo (etoposide + cisplatin/carboplatin, EP/EC).

Conference:

Presenting Author:

Authors: Cao D, Li X, Li R, Wang X, Yang Y,

Keywords: neuroendocrine carcinoma, First-line, chemotherapy, camrelizumab,

#4291 Novel genomic score predicts survival with immune checkpoint blockade in neuroendocrine neoplasms

Introduction: Immune checkpoint inhibition (ICI) has activity in Grade 3 (G3) neuroendocrine neoplasms (NENs) but predictive biomarkers of overall survival (OS) are currently lacking.

Conference:

Presenting Author:

Authors: Brar T, Sukrithan V, Le D, Xu M, Olowookere C,

Keywords: Neuroendocrine Neoplasm, Immunotherapy, Ipilimumab, Nivolumab, Immune checkpoint inhibitor, biomarker, genomic score,

#4228 Evaluation of the impact of indoleamine 2,3-deoxygenase (IDO) enzyme activity in neuroendocrine tumors (NETs)

Introduction: Indoleamine 2,3-deoxygenase (IDO) enzyme, by inducing L-tryptophan (Trp) depletion and L-kynurenine (kyn) accumulation, contributes to the formation of an immunosuppressive microenvironment. Some studies highlighted that patient with cancer in treatment with immune checkpoint inhibitors (ICI) and with low Kyn/Trp values showed a better PFS and OS, but there are no data for NETs.

Conference:

Presenting Author: Mancini C

Authors: Mancini C, Mazzilli R, Zamponi V, Motta C, Salerno G,

Keywords: neuroendocrine tumor, IDO enzyme, Kyn/Trp ratio, immunotherapy,

#4005 Camrelizumab plus chemotherapy as first-line treatment for advanced extrapulmonary neuroendocrine carcinoma: An investigator-initiated phase 2 study (CAMEC trial)

Introduction: The standard chemotherapy composed of etoposide and cisplatin/carboplatin (EP/EC) for extra-pulmonary neuroendocrine carcinoma (NEC) is of limited efficacy.

Conference:

Presenting Author:

Authors: Li X, Li R, Cheng K, Cao D,

Keywords: extra-pulmonary NEC, first-line, immune checkpoint inhibitor, chemotherapy,